Since we did not find any overexpression of Bcl-2 family members in peripheral blood of RA/SLE patient samples and our BH3 mimetic results showed more effects in healthy controls, we have not yet sufficient data to support the use of any of the tested BH3 mimetic drugs in the treatment of autoimmunity. This evidence concerns the gene BCL2 and systemic lupus erythematosus.